**The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment**

Iris Lavon

*Leslie and Michael Gaffin Center for Neuro-Oncology and Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel* 

#### **1. Introduction**

74 Novel Therapeutic Concepts in Targeting Glioma

Yan, W.; Zhang, W.; Sun, L.; Liu, Y.; You, G.; Wang, Y.; Kang, C.; You, Y. & Jiang, T. (2011).

Zhang, B. & Farwell, M.A. (2008). microRNAs: a new emerging class of players for disease

Zhang, C.; Han, L.; Zhang, A.; Yang, W.; Zhou, X.; Pu, P.; Du, Y.; Zeng, H. & Kang, C.

Zhang, C.Z.; Zhang, J.X.; Zhang, A.L.; Shi, Z.D.; Han, L.; Jia, Z.F.; Yang, W.D.; Wang, G.X.;

Zhang, J.; Han, L.; Ge, Y.; Zhou, X.; Zhang, A.; Zhang, C.; Zhong, Y.; You, Y.; Pu, P. & Kang,

Zhou, X.; Ren, Y.; Moore, L.; Mei, M.; You, Y.; Xu, P.; Wang, B.; Wang, G.; Jia, Z.; Pu, P.;

Zhou, X.; Zhang, J.; Jia, Q.; Ren, Y.; Wang, Y.; Shi, L.; Liu, N.; Wang, G.; Pu, P.; You, Y. &

caspase 9 and 3. *Oncol Rep,* Vol.24, No.1, pp. 195-201, ISSN 1791-2431 Ziegler, D.S.; Wright, R.D.; Kesari, S.; Lemieux, M.E.; Tran, M.A.; Jain, M.; Zawel, L. & Kung,

status. *Lab Invest,* Vol.90, No.2, pp. 144-155, ISSN 1530-0307

Vol.118, No.9, pp. 3109-3122, ISSN 0021-9738

115, ISSN 1872-6240

ISSN 1476-4598

Vol.36, No.6, pp. 1503-1512, ISSN 1791-2423

Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. *Brain Res,* Vol.1411, pp. 108-

diagnostics and gene therapy. *J Cell Mol Med,* Vol.12, No.1, pp. 3-21, ISSN 1582-1838

(2010a). Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. *Int J Oncol,*

Jiang, T.; You, Y.P.; Pu, P.Y.; Cheng, J.Q. & Kang, C.S. (2010b). MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. *Mol Cancer,* Vol.9, pp. 229,

C. (2010c). miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. *Int J Oncol,* Vol.36, No.4, pp. 913-920, ISSN 1791-2423

Zhang, W. & Kang, C. (2010a). Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN

Kang, C. (2010b). Reduction of miR-21 induces glioma cell apoptosis via activating

A.L. (2008). Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. *J Clin Invest,*

MicroRNAs (miRNAs) are a class of single-stranded non-coding RNAs that average 22 nucleotides in length. They regulate gene expression by binding to imperfectly matched sequences in the 3'-untranslated region (3'UTR) of target mRNAs, resulting in either translational repression or destabilization/degradation of their target mRNAs1-7. miRNAs play an important role in nearly all cancer types, where they modulate key tumorigenesis processes, such as metastasis, apoptosis, proliferation, and angiogenesis. Each miRNA can affect several different mRNAs and, depending on the target, has the potential to function as an oncogene and/or tumor suppressor.

It has recently been shown that miRNAs play important roles in gliomas 8-19. A number of miRNAs, such as miR-21, miR-221, miR-222, miR-10b, and the miR-26a cluster 15,19, together with the genes cyclin-dependent kinase 4 (CDK4) and CENTG1, are upregulated in gliomas and appear to act in an oncogenic fashion. Other miRNAs, such as miR-1248, miR-1378, miR-34a12,13, miR-12816, miR-32617 and members of the let-718 family, are downregulated indicating a tumor suppressive nature.

Several important target mRNAs and pathways have been identified for these oncomiRNAs and tumor suppressor miRNAs. For example, miR-34a is downregulated in glioblastomas as a result of p53 dysfunction, while restoring the expression of miR-34a12 or miR-718 in glioma cells can strongly inhibit oncogenic pathways, such as Ras and Akt.

In addition to the singly transcribed miRNAs, our studies demonstrated that several miRNA clusters were shown to be deregulated in gliomas and might have an important role in the disease process. These clusters comprise the miR17 family, miR183-182, and the SC-specific clusters (miR367-302 and miR371-373), which are upregulated in gliomas. Because the massive cluster of 53 miRNAs on chromosome 14q32.31 is downregulated, it may represent the largest tumor suppressive miRNA cluster20. Some of these clusters, such as miR17-92, which is one of the three miRNA clusters related to the miR-17 family, reportedly have a pro-oncogenic roles in other type of cancers21.

The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment 77

mature forms increased 39. Few studies shed some light on this mechanism by showing that the let-7 targets, the RNA-binding proteins Lin28 and Lin28B, bind to the loop region of let-7 precursors, which blocks the processing of let-7 at either the Drosha or the Dicer levels40,41. This Lin28-mediated degradation of let-7 likely plays a key role not only in development but

This mechanism was suggested also for gliomas based on an array study on human glioma tumors and mouse and human glioma cell lines. The study demonstrated that the majority of the differentially expressed miRNAs were located in regions susceptible to genetic

This is illustrated bychanges in chromatin structures that are induced by covalent modifications of histones and/or DNA methylation44. For example, the epigenetic silencing of the miR-124 loci has been observed in brain tumors 8 and precancerous lesions45. The epigenetic masking of miR-124 induces activation of the oncogene cyclin-dependent kinase

It has been shown that the Let-7 family is downregulated in gliomas18. This miRNA family is considered to be comprised of tumor suppressor miRNAs. The let-7a-3 locus is generally methylated in normal tissues, but it is hypomethylated in some types of cancers. The methylation levels of let-7a-3 correlate inversely with let-7a-3 pri-miRNA expression levels; thus, Let-7a-3 hypomethylation facilitates the epigenetic reactivation of the gene resulting in elevated expression of let-7a-3 and enhanced tumor phenotypes and oncogenic changes39,46. Another example is miR-128, which is not regulated by epigenetics, but has been shown to play a role in the epigenesis of glioma SCs. Its downregulation in glioma tissue causes the elevated expression of Bmi-1, one of the polycomb group of genes that function as epigenetic silencers, which enhances cancer stem cell self-renewal through chromatin

**4. The involvement of miRNAs in pathways that may promote gliomagenesis** 

miRNAs have been shown to act as both oncogenes or tumor suppressor genes and, thus, affect pathways that bestow nearly all hallmarks of cancer47,48. These miRNAs can, in turn,

For a tumor to become independent from external growth factor signals, it requires the activation of different cell proliferation and survival pathways, such as those mediated by epidermal growth factor receptor (EGFR) and Akt, which play a central role in glioblastomas. It has been demonstrated that miR-7 directly inhibits the expression of EGFR38,49 and its downstream effector, Raf1, and suppresses the AKT pathway by targeting upstream regulators. Indeed, transfection with "mimic" miR-7 oligonucleotides decreased viability and invasiveness and induces cell cycle arrest and apoptosis of glioblastoma cell

(CDK)-6 and consequent phosphorylation of Rb, resulting in accelerated cell growth.

b. *Localization of miRNAs inside or close to cancer-associated genomic regions*42,43.

also in tumorigenesis.

alterations in cancer 20.

remodeling16.

lines38,49.

**and tumor progression** 

*a. Sustaining proliferative signaling* 

promote gliomagenesis and tumor progression.

*c. Epigenetic regulation of miRNA expression.* 

We have recently shown that gliomas share miRNA expression profiles that are similar to neural precursor cells20. This result is in agreement with the finding that gliomas contain heterogeneous neoplastic cell populations that phenotypically resemble undifferentiated or immature glial cells.

The study of miRNAs is rapidly developing and could considerably change the current conception of glioma biology. Detecting and quantifying microRNAs in tissue and serum will soon be routinely used for tumor classification and grading as well as diagnostic and prognostic testing for gliomas. For example, high levels of miR-21, miR-182 and miR-196 as well as low expression of miR-181b and miR-106a are associated with poor overall survival in patients with malignant gliomas22-24, and these miRNAs might function as biomarkers of glioma progression. Furthermore, miR-195, miR-455-3p, miR-10a25 and the miR-181 family26 have been linked to treatment resistance, and assessing the relative expression levels of these miRNAs may assist with the design of personalized treatments.

New knowledge regarding the involvement of miRNAs in glioma biology has provided opportunities for the use of miRNAs or their inhibitors as potential candidates for the brain tumor treatments. However, such a therapeutic approach may be considerably challenging in light of several barriers *in vivo,* such as the blood–brain barrier27, which can prevent miRNAs or their antagonists from entering the brain.

### **2. MicroRNA regulation of gene expression**

miRNAs regulate gene expression inhibition through several proposed mechanisms. One model suggests that there is competition between RISC and eIF4E for mRNA binding, which represses initiation. A second model has proposed that Ago recruits eIF6 and, thus, prevents the association of the 60S ribosomal subunit with the 40S preinitiation complex28,29. The third model suggests that miRNAs destabilize target mRNAs by de-adenylation and subsequent decapping30-34. It was recently observed that AGO-2, mature miRNAs and translationally repressed mRNAs can accumulate in cytoplasmic processing bodies (P-bodies)35. These bodies are enriched with proteins involved in translational repression and in mRNA deadenylation, decapping and degradation. Thus, they might function not only in storage but also in the decay of repressed mRNAs. However, it remains to be established whether the accumulation of these proteins in P-bodies is the cause rather than the consequence of target mRNA silencing36,37.

### **3. Mechanisms responsible for altered miRNA expression in gliomas**

Aberrant miRNA expression and function has been frequently observed in gliomas. A number of mechanisms are responsible for altered miRNA expression in cancer:

*a. Altered transcription regulation or abnormalities in miRNA processing.* 

For miR-7, normal pre-miRNA levels were found to be associated with reduced mature miRNA levels in glioblastomas, where it was proven that the reduction in the miR-7 processing was occurred at the pri- to pre-miRNA processing step38. Various members of the let-7 family are regulated post-transcriptionally during embryonic brain development, the neural differentiation of embryonic stem cells (SC) and in embryocarcinoma. In these settings, the levels of the pre-miRNAs were consistent during differentiation; however, the mature forms increased 39. Few studies shed some light on this mechanism by showing that the let-7 targets, the RNA-binding proteins Lin28 and Lin28B, bind to the loop region of let-7 precursors, which blocks the processing of let-7 at either the Drosha or the Dicer levels40,41. This Lin28-mediated degradation of let-7 likely plays a key role not only in development but also in tumorigenesis.

#### b. *Localization of miRNAs inside or close to cancer-associated genomic regions*42,43.

This mechanism was suggested also for gliomas based on an array study on human glioma tumors and mouse and human glioma cell lines. The study demonstrated that the majority of the differentially expressed miRNAs were located in regions susceptible to genetic alterations in cancer 20.

#### *c. Epigenetic regulation of miRNA expression.*

76 Novel Therapeutic Concepts in Targeting Glioma

We have recently shown that gliomas share miRNA expression profiles that are similar to neural precursor cells20. This result is in agreement with the finding that gliomas contain heterogeneous neoplastic cell populations that phenotypically resemble undifferentiated or

The study of miRNAs is rapidly developing and could considerably change the current conception of glioma biology. Detecting and quantifying microRNAs in tissue and serum will soon be routinely used for tumor classification and grading as well as diagnostic and prognostic testing for gliomas. For example, high levels of miR-21, miR-182 and miR-196 as well as low expression of miR-181b and miR-106a are associated with poor overall survival in patients with malignant gliomas22-24, and these miRNAs might function as biomarkers of glioma progression. Furthermore, miR-195, miR-455-3p, miR-10a25 and the miR-181 family26 have been linked to treatment resistance, and assessing the relative expression levels of

New knowledge regarding the involvement of miRNAs in glioma biology has provided opportunities for the use of miRNAs or their inhibitors as potential candidates for the brain tumor treatments. However, such a therapeutic approach may be considerably challenging in light of several barriers *in vivo,* such as the blood–brain barrier27, which can prevent

miRNAs regulate gene expression inhibition through several proposed mechanisms. One model suggests that there is competition between RISC and eIF4E for mRNA binding, which represses initiation. A second model has proposed that Ago recruits eIF6 and, thus, prevents the association of the 60S ribosomal subunit with the 40S preinitiation complex28,29. The third model suggests that miRNAs destabilize target mRNAs by de-adenylation and subsequent decapping30-34. It was recently observed that AGO-2, mature miRNAs and translationally repressed mRNAs can accumulate in cytoplasmic processing bodies (P-bodies)35. These bodies are enriched with proteins involved in translational repression and in mRNA deadenylation, decapping and degradation. Thus, they might function not only in storage but also in the decay of repressed mRNAs. However, it remains to be established whether the accumulation of these proteins in P-bodies is the cause rather than the consequence of target

**3. Mechanisms responsible for altered miRNA expression in gliomas** 

number of mechanisms are responsible for altered miRNA expression in cancer:

*a. Altered transcription regulation or abnormalities in miRNA processing.* 

Aberrant miRNA expression and function has been frequently observed in gliomas. A

For miR-7, normal pre-miRNA levels were found to be associated with reduced mature miRNA levels in glioblastomas, where it was proven that the reduction in the miR-7 processing was occurred at the pri- to pre-miRNA processing step38. Various members of the let-7 family are regulated post-transcriptionally during embryonic brain development, the neural differentiation of embryonic stem cells (SC) and in embryocarcinoma. In these settings, the levels of the pre-miRNAs were consistent during differentiation; however, the

these miRNAs may assist with the design of personalized treatments.

miRNAs or their antagonists from entering the brain.

**2. MicroRNA regulation of gene expression** 

immature glial cells.

mRNA silencing36,37.

This is illustrated bychanges in chromatin structures that are induced by covalent modifications of histones and/or DNA methylation44. For example, the epigenetic silencing of the miR-124 loci has been observed in brain tumors 8 and precancerous lesions45. The epigenetic masking of miR-124 induces activation of the oncogene cyclin-dependent kinase (CDK)-6 and consequent phosphorylation of Rb, resulting in accelerated cell growth.

It has been shown that the Let-7 family is downregulated in gliomas18. This miRNA family is considered to be comprised of tumor suppressor miRNAs. The let-7a-3 locus is generally methylated in normal tissues, but it is hypomethylated in some types of cancers. The methylation levels of let-7a-3 correlate inversely with let-7a-3 pri-miRNA expression levels; thus, Let-7a-3 hypomethylation facilitates the epigenetic reactivation of the gene resulting in elevated expression of let-7a-3 and enhanced tumor phenotypes and oncogenic changes39,46. Another example is miR-128, which is not regulated by epigenetics, but has been shown to play a role in the epigenesis of glioma SCs. Its downregulation in glioma tissue causes the elevated expression of Bmi-1, one of the polycomb group of genes that function as epigenetic silencers, which enhances cancer stem cell self-renewal through chromatin remodeling16.

#### **4. The involvement of miRNAs in pathways that may promote gliomagenesis and tumor progression**

miRNAs have been shown to act as both oncogenes or tumor suppressor genes and, thus, affect pathways that bestow nearly all hallmarks of cancer47,48. These miRNAs can, in turn, promote gliomagenesis and tumor progression.

#### *a. Sustaining proliferative signaling*

For a tumor to become independent from external growth factor signals, it requires the activation of different cell proliferation and survival pathways, such as those mediated by epidermal growth factor receptor (EGFR) and Akt, which play a central role in glioblastomas. It has been demonstrated that miR-7 directly inhibits the expression of EGFR38,49 and its downstream effector, Raf1, and suppresses the AKT pathway by targeting upstream regulators. Indeed, transfection with "mimic" miR-7 oligonucleotides decreased viability and invasiveness and induces cell cycle arrest and apoptosis of glioblastoma cell lines38,49.

The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment 79

overexpression of these miRNAs increases glioma cell proliferation *in-vitro* and induces glioma growth in a subcutaneous mouse model54. The inhibition of miR-10b, which is strongly upregulated in gliomas, reduces glioma cell growth through cell-cycle arrest and apoptosis. These cellular responses are mediated by augmented expression of its direct

In addition to the role of miR-221/222 in cell growth and cell cycle progression, it has been demonstrated that miR-221/222 directly regulates apoptosis by targeting p53-upregulatedmodulator-of-apoptosis (PUMA) in glioblastoma. PUMA binds to Bcl-2 and Bcl-XL through a BH3 domain and the exogenous expression of PUMA results in an extremely rapid and profound apoptosis56. Thus, the forced expression of miR-221/222 downregulates PUMA and induces cell survival, whereas the knockdown of miR-221/222 induces PUMA expression and cell apoptosis as well as decreases tumor growth in a xenograft model57.

Recent studies have revealed important roles for miRNAs such as the endothelial cell (EC) restricted miRNA miR-126 as well as miR-378, miR-296, miR-92a and the miR-17-92 cluster

The level of the angiomir miR-296, which inhibits the degradation of the VEGF receptor, is increased in EC cells co-cultured with glioma cells or in response to angiogenic growth factors (including VEGF). When miR-296 is inhibited *in vivo*, the vascularization of tumor xenografts decreases59. miR-93, one of the miRNAs within the miR-106b-25 cluster, a member of the miR-17 family, enhances cell survival, promotes sphere formation and augments tumor growth. *In vivo* studies revealed that miR-93-expressing cells induced blood vessel formation, likely through targeting integrin-β8, allowing blood vessels to extend to tumor tissues in high densities. These findings show that miR-93 promotes tumor

As mentioned above, miR-21 is overexpressed in gliomas. The metalloproteinase (MMPS) inhibitors RECK and TIMP3 are two targets of miR-21. RECK is a membrane-anchorage regulator, while TIMP3 is an extracellular matrix (ECM)-bound protease inhibitor. Treatment with antisense oligonucleotides to miR-21 in glioma cell lines and in a nude mouse model of human glioma resulted in elevated levels of RECK and TIMP3 and, therefore, reduced MMP activities. Thus, downregulation of miR-21 in glioma cells leads to

miR-10b is highly expressed in many tumors, including glioblastomas. It was found that miR-10b induces glioma cell invasion by modulating the expression of the tumor invasion factors MMP-14 and uPAR through directly targeting HOXD10. Accordingly, glioma cells lost their invasive ability when they were treated with specific antisense oligonucleotides to

Not surprisingly, additional miRNAs are currently being identified and associated with ECM reorganization in relationship to cancer. Like miR-21 and 10b, miR-146b has also been demonstrated to play a role in glioma cell invasion60. However, miR-146b does not function

in regulating angiogenesis. Thus, these have been termed angiomirs58.

growth and angiogenesis through the suppression of integrin-β8 expression.

targets, including p21 and CDKN2A/p1655.

*c. Resisting cell death* 

*d. Inducing angiogenesis* 

*e. Activating invasion and metastasis* 

miR-10b.

a decrease in their migratory and invasion abilities11.

The altered regulation/activation of RAS proteins, which process signals downstream of growth receptors, plays a key role in the deregulation of multiple proliferation pathways in most types of tumors, including gliomas. Decreased levels of let-7 in gliomas correlate inversely with overexpression of RAS proteins, while restoring let-7 expression reduces the expression of RAS in glioma cell lines resulting in tumor growth inhibition *in vitro* and *in vivo*18. Moreover, the activation/overexpression of RAS leads to the upregulation of miR-21 *in-vitro* and *in-vivo*. Mir-21 exerts its oncogenic effect by downregulating the phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4)50. In a number of human glioblastoma cell lines, such as T98G, A172, U87, and U251, the expression of PDCD4 protein correlates inversely with expression of miR-21. The downregulation of miR-21 in those cell lines leads to decreased proliferation, increased apoptosis, and decreased colony formation on soft agar51.

DNA amplification of an onco-amplicon was observed in a subset of high-grade gliomas. This onco-amplicon consists of miR26a-2 and the oncoproteins CDK4 and CENTG1, which regulate the RB1 and PI3 kinase/AKT pathways, respectively. miR-26a alone can functionally target PTEN, RB1, and MAP3K2/MEKK2 protein expression, thereby increasing AKT activation, promoting proliferation, and decreasing c-JUN N-terminal kinase-dependent apoptosis *in vitro* and *in vivo*. The overexpression of miR-26a in cells overexpressing CDK4 or CENTG1 further promotes tumor growth *in vivo*. Glioblastoma patients harboring this amplification display markedly decreased survival15,19.

#### *b. Evading growth suppressors*

miRNAs may also affect cell proliferation by controlling cell cycle regulators. The E2Fs transcription factor family plays a pivotal role in cell cycle progression. In response to mitogenic signaling, pRB is sequentially phosphorylated by the CDK/cyclin complexes leading to activation of E2F-responsive genes to promote cell cycle progression52. This pathway can be inhibited by several miRNAs. For example, miR-137, and miR-124a inhibit CDK6 expression in different cancer cell lines, including gliomas8, where the transfection of miR-124 or miR-137 has been shown to prevent cell cycle progression in glioblastoma cell lines, which is associated with the decreased expression of CDK6 and pRB proteins8. miR-34a, which is transcriptionally activated by p53, can target both CDK6 and cyclin D1 preventing the downstream pro-survival signaling of the cyclin/CDK pathway. Restoring the expression of the underexpressed miR-34a in glioma cell lines downregulates CDK6 protein expressions and inhibits cell proliferation.12

The negative regulators of the cyclin/CDK pathway, such as members of the Cip/Kip family (p21, p27 and p57) and the INK4a/ARF family (p14 and p16), are regulated by several miRNAs. Upregulation of these miRNAs may inhibit these negative regulators and result in the proliferation and survival of the cells.

The miRNA clusters miR-106b-25 and miR-17-92 have anti-proliferative and pro-apoptotic activities in different tumor types through the inhibition of p21 in addition to other genes. Although they are also upregulated in gliomas20, their role in the inhibition of p21 or other negative regulators of cyclin/CDK remain to be elucidated. High levels of miR-221/222, which targets both p27 and p57, appear in glioblastomas. Functional studies showed that miR-221/222 prevents quiescence when elevated during growth factor deprivation and induces precocious S-phase entry, thereby triggering cell death53. In addition, the overexpression of these miRNAs increases glioma cell proliferation *in-vitro* and induces glioma growth in a subcutaneous mouse model54. The inhibition of miR-10b, which is strongly upregulated in gliomas, reduces glioma cell growth through cell-cycle arrest and apoptosis. These cellular responses are mediated by augmented expression of its direct targets, including p21 and CDKN2A/p1655.

#### *c. Resisting cell death*

78 Novel Therapeutic Concepts in Targeting Glioma

The altered regulation/activation of RAS proteins, which process signals downstream of growth receptors, plays a key role in the deregulation of multiple proliferation pathways in most types of tumors, including gliomas. Decreased levels of let-7 in gliomas correlate inversely with overexpression of RAS proteins, while restoring let-7 expression reduces the expression of RAS in glioma cell lines resulting in tumor growth inhibition *in vitro* and *in vivo*18. Moreover, the activation/overexpression of RAS leads to the upregulation of miR-21 *in-vitro* and *in-vivo*. Mir-21 exerts its oncogenic effect by downregulating the phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4)50. In a number of human glioblastoma cell lines, such as T98G, A172, U87, and U251, the expression of PDCD4 protein correlates inversely with expression of miR-21. The downregulation of miR-21 in those cell lines leads to decreased proliferation, increased apoptosis, and decreased colony

DNA amplification of an onco-amplicon was observed in a subset of high-grade gliomas. This onco-amplicon consists of miR26a-2 and the oncoproteins CDK4 and CENTG1, which regulate the RB1 and PI3 kinase/AKT pathways, respectively. miR-26a alone can functionally target PTEN, RB1, and MAP3K2/MEKK2 protein expression, thereby increasing AKT activation, promoting proliferation, and decreasing c-JUN N-terminal kinase-dependent apoptosis *in vitro* and *in vivo*. The overexpression of miR-26a in cells overexpressing CDK4 or CENTG1 further promotes tumor growth *in vivo*. Glioblastoma

miRNAs may also affect cell proliferation by controlling cell cycle regulators. The E2Fs transcription factor family plays a pivotal role in cell cycle progression. In response to mitogenic signaling, pRB is sequentially phosphorylated by the CDK/cyclin complexes leading to activation of E2F-responsive genes to promote cell cycle progression52. This pathway can be inhibited by several miRNAs. For example, miR-137, and miR-124a inhibit CDK6 expression in different cancer cell lines, including gliomas8, where the transfection of miR-124 or miR-137 has been shown to prevent cell cycle progression in glioblastoma cell lines, which is associated with the decreased expression of CDK6 and pRB proteins8. miR-34a, which is transcriptionally activated by p53, can target both CDK6 and cyclin D1 preventing the downstream pro-survival signaling of the cyclin/CDK pathway. Restoring the expression of the underexpressed miR-34a in glioma cell lines downregulates CDK6

The negative regulators of the cyclin/CDK pathway, such as members of the Cip/Kip family (p21, p27 and p57) and the INK4a/ARF family (p14 and p16), are regulated by several miRNAs. Upregulation of these miRNAs may inhibit these negative regulators and

The miRNA clusters miR-106b-25 and miR-17-92 have anti-proliferative and pro-apoptotic activities in different tumor types through the inhibition of p21 in addition to other genes. Although they are also upregulated in gliomas20, their role in the inhibition of p21 or other negative regulators of cyclin/CDK remain to be elucidated. High levels of miR-221/222, which targets both p27 and p57, appear in glioblastomas. Functional studies showed that miR-221/222 prevents quiescence when elevated during growth factor deprivation and induces precocious S-phase entry, thereby triggering cell death53. In addition, the

patients harboring this amplification display markedly decreased survival15,19.

formation on soft agar51.

*b. Evading growth suppressors* 

protein expressions and inhibits cell proliferation.12

result in the proliferation and survival of the cells.

In addition to the role of miR-221/222 in cell growth and cell cycle progression, it has been demonstrated that miR-221/222 directly regulates apoptosis by targeting p53-upregulatedmodulator-of-apoptosis (PUMA) in glioblastoma. PUMA binds to Bcl-2 and Bcl-XL through a BH3 domain and the exogenous expression of PUMA results in an extremely rapid and profound apoptosis56. Thus, the forced expression of miR-221/222 downregulates PUMA and induces cell survival, whereas the knockdown of miR-221/222 induces PUMA expression and cell apoptosis as well as decreases tumor growth in a xenograft model57.

#### *d. Inducing angiogenesis*

Recent studies have revealed important roles for miRNAs such as the endothelial cell (EC) restricted miRNA miR-126 as well as miR-378, miR-296, miR-92a and the miR-17-92 cluster in regulating angiogenesis. Thus, these have been termed angiomirs58.

The level of the angiomir miR-296, which inhibits the degradation of the VEGF receptor, is increased in EC cells co-cultured with glioma cells or in response to angiogenic growth factors (including VEGF). When miR-296 is inhibited *in vivo*, the vascularization of tumor xenografts decreases59. miR-93, one of the miRNAs within the miR-106b-25 cluster, a member of the miR-17 family, enhances cell survival, promotes sphere formation and augments tumor growth. *In vivo* studies revealed that miR-93-expressing cells induced blood vessel formation, likely through targeting integrin-β8, allowing blood vessels to extend to tumor tissues in high densities. These findings show that miR-93 promotes tumor growth and angiogenesis through the suppression of integrin-β8 expression.

#### *e. Activating invasion and metastasis*

As mentioned above, miR-21 is overexpressed in gliomas. The metalloproteinase (MMPS) inhibitors RECK and TIMP3 are two targets of miR-21. RECK is a membrane-anchorage regulator, while TIMP3 is an extracellular matrix (ECM)-bound protease inhibitor. Treatment with antisense oligonucleotides to miR-21 in glioma cell lines and in a nude mouse model of human glioma resulted in elevated levels of RECK and TIMP3 and, therefore, reduced MMP activities. Thus, downregulation of miR-21 in glioma cells leads to a decrease in their migratory and invasion abilities11.

miR-10b is highly expressed in many tumors, including glioblastomas. It was found that miR-10b induces glioma cell invasion by modulating the expression of the tumor invasion factors MMP-14 and uPAR through directly targeting HOXD10. Accordingly, glioma cells lost their invasive ability when they were treated with specific antisense oligonucleotides to miR-10b.

Not surprisingly, additional miRNAs are currently being identified and associated with ECM reorganization in relationship to cancer. Like miR-21 and 10b, miR-146b has also been demonstrated to play a role in glioma cell invasion60. However, miR-146b does not function

The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment 81

in different types of cancers (e.g., LOH on chromosome 14q32.31, or the amplification of chromosome 13q31.3). Together, these findings suggest that NPCs may be the originating cells in gliomas and that aberrations in critical regions might be necessary to maintain the

A recent paper analyzed microRNA expression data from The Cancer Genome Atlas (TCGA) and identified five clinically and genetically distinct glioblastoma subclasses related to a different neural precursor cell types. Thus, like us they also suggested that glioblastomas can arise from neural precursor cells but emphasized that the cell of origin

**6. microRNAs as biomarkers for the diagnosis and prognosis of gliomas** 

As reviewed above, a large number of recent studies have discovered that miRNAs play important regulatory roles in a variety of cellular functions in gliomas. Other papers have demonstrated that miRNAs can be used for tumor classification and grading66,67 in addition to the diagnosis23, prognosis22,23 and prediction of therapeutic efficacy69, 69 of tumors. The discovery of miRNAs in the serum of cancer patients70 opened up the exciting possibility of using miRNAs as non-invasive biomarkers. Thus, detecting and quantifying microRNAs may soon be used in routine clinical practice for diagnostic and

The expression levels of miR-18222 and miR-19623 are significant in correlation with World Health Organization glioma grading (P < 0.001). Multivariate analysis showed that the expression of both these miRNAs is a predictor of overall survival in glioblastoma patients 22,23. Analysis of miRNA expression data in glioblastoma patients (n = 222) derived from the TCGA dataset identified an expression signature of ten miRNAs that can predict glioblastoma (GBM) patient survival71. In astrocytomas, the downregulation of miR-137 has been shown to be associated with advanced clinical stages of the disease; and the low expression levels of miR-181b and miR-106a, or high expression of miR-21, are significantly associated with poor patient survival24. Several papers aimed to identify the miRNAs specifically involved in the acquisition of temozolomide (TMZ) resistance in glioblastoma. In one article, the authors established resistant variant U251R cells from a TMZ-sensitive glioblastoma cell line (U251MG) and performed miRNA microarray on both the resistant and sensitive cell lines. The results showed that miR-195, miR-455-3p and miR-10a\* were the three most upregulated miRNAs in the resistant cells. When miR-195 was reduced, the resistant cells displayed a moderate cell killing effect, and the combination with TMZ strongly enhanced this effect25. Another article examined the correlation between the expression levels of selected microRNAs in 22 primary glioblastomas with response to concomitant therapy (e.g., chemoradiotherapy with TMZ). They found that miR-181b and miR-181c were significantly downregulated in patients who responded to concomitant

Over many decades, it has been shown that cell-free DNA and RNA is present in the circulation and may represent potential biomarkers. We have demonstrated that tumorspecific DNA can be detected in the serum of glioma patients and is a potentially promising tool for brain tumor diagnosis72. Skog et al. was the first to demonstrate that

stem cell nature of gliomas20.

prognostic glioma testing.

could arise from multiple stages of differentiation68.

therapy compared to patients with progredient disease26.

through the suppression of ECM inhibitors; rather, its loss in gliomas allows the upregulation of MMP16, which might cause proteolysis of ECM components, such as type III collagen. Thus, low levels of miR-146b contribute to the migration and invasion of glioma60.

#### *f. Reprogramming energy metabolism*

Pyruvate kinase type M2 (PKM2) is one of four isoenzymes of pyruvate kinase, which catalyzes the last step within glycolysis. This enzyme is normally thought to be embryonically restricted; however, it has been shown to be expressed in cancerous cells61. Recently, it was shown that the levels of PKM2 negatively correlate with the levels of miR-326, suggesting a regulatory relationship between PKM2 and miR-326. Furthermore, miR-326 decreased the glioma metabolic activity by decreasing ATP levels, suggesting that miR-326 could regulate glioma metabolism through the downregulation of PKM262.

### **5. The glioma microRNA expression signature**

Differential miRNA expression in gliomas was first reported by Ciafre`63 and Chan64. Their study revealed that miR-2164 and miR-221 are upregulated, whereas miR-128, miR-181a, miR-181b and miR-181c are downregulated, in glioblastoma63. Other array-based approaches identified that the expression of miR-124, miR-128a, and miR-137 are decreased in anaplastic astrocytomas and glioblastomas8. In addition, miR-124 is decreased in oligodendroglial tumors65 relative to non-neoplastic control brain tissues.

The expression levels of miR-124 and miR-137 were increased during the differentiation of mouse neural progenitor cells (NPCs) following growth factor withdrawal. Thus, the authors have suggested that these specific miRNAs display "stemness" of glioma cells and that alteration of the levels of these miRNAs may induce differentiation8.

While these studies compared microRNA expression in gliomas relative to control tissues, other studies explored the role of miRNAs in glioma progression. One study investigated miRNA expression profiles in primary WHO grade II gliomas that spontaneously progressed to WHO grade IV secondary glioblastomas. They identified 12 miRNAs (miR-9, miR-15a, miR-16, miR-17, miR-19a, miR-20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) that were upregulated and two miRNAs (miR-184 and miR-328) that were downregulated upon glioma progression66. Other studies have compared the differential miRNA expression between astrocytomas and glioblastomas and revealed a 23-miRNA expression signature that can discriminate glioblastomas from anaplastic astrocytomas with an overall diagnostic accuracy of 89.7%67.

Our study compared the miRNA expression signatures of glial tumors, embryonic SCs, NPCs and normal adult brains from both human and mouse tissues. We demonstrated that all gliomas displayed NPC-like miRNA signatures. About half of the miRNAs expressed in the NPCs-glioma shared profile were clustered in seven genomic regions. These clusters comprised the miR17 family (3 clusters), miR183-182, and the SC-specific clusters miR367- 302 and miR371-373, which are upregulate. They also contained the bipartite cluster of 7*+*46 miRNAs on chromosome 14q32.31, which is downregulated in the shared expression profile. These seven regions are particularly prone to genetic and/or epigenetic aberrations

through the suppression of ECM inhibitors; rather, its loss in gliomas allows the upregulation of MMP16, which might cause proteolysis of ECM components, such as type III collagen. Thus, low levels of miR-146b contribute to the migration and invasion of

Pyruvate kinase type M2 (PKM2) is one of four isoenzymes of pyruvate kinase, which catalyzes the last step within glycolysis. This enzyme is normally thought to be embryonically restricted; however, it has been shown to be expressed in cancerous cells61. Recently, it was shown that the levels of PKM2 negatively correlate with the levels of miR-326, suggesting a regulatory relationship between PKM2 and miR-326. Furthermore, miR-326 decreased the glioma metabolic activity by decreasing ATP levels, suggesting that miR-

Differential miRNA expression in gliomas was first reported by Ciafre`63 and Chan64. Their study revealed that miR-2164 and miR-221 are upregulated, whereas miR-128, miR-181a, miR-181b and miR-181c are downregulated, in glioblastoma63. Other array-based approaches identified that the expression of miR-124, miR-128a, and miR-137 are decreased in anaplastic astrocytomas and glioblastomas8. In addition, miR-124 is decreased in

The expression levels of miR-124 and miR-137 were increased during the differentiation of mouse neural progenitor cells (NPCs) following growth factor withdrawal. Thus, the authors have suggested that these specific miRNAs display "stemness" of glioma cells and

While these studies compared microRNA expression in gliomas relative to control tissues, other studies explored the role of miRNAs in glioma progression. One study investigated miRNA expression profiles in primary WHO grade II gliomas that spontaneously progressed to WHO grade IV secondary glioblastomas. They identified 12 miRNAs (miR-9, miR-15a, miR-16, miR-17, miR-19a, miR-20a, miR-21, miR-25, miR-28, miR-130b, miR-140 and miR-210) that were upregulated and two miRNAs (miR-184 and miR-328) that were downregulated upon glioma progression66. Other studies have compared the differential miRNA expression between astrocytomas and glioblastomas and revealed a 23-miRNA expression signature that can discriminate glioblastomas from anaplastic astrocytomas with

Our study compared the miRNA expression signatures of glial tumors, embryonic SCs, NPCs and normal adult brains from both human and mouse tissues. We demonstrated that all gliomas displayed NPC-like miRNA signatures. About half of the miRNAs expressed in the NPCs-glioma shared profile were clustered in seven genomic regions. These clusters comprised the miR17 family (3 clusters), miR183-182, and the SC-specific clusters miR367- 302 and miR371-373, which are upregulate. They also contained the bipartite cluster of 7*+*46 miRNAs on chromosome 14q32.31, which is downregulated in the shared expression profile. These seven regions are particularly prone to genetic and/or epigenetic aberrations

326 could regulate glioma metabolism through the downregulation of PKM262.

oligodendroglial tumors65 relative to non-neoplastic control brain tissues.

that alteration of the levels of these miRNAs may induce differentiation8.

**5. The glioma microRNA expression signature** 

an overall diagnostic accuracy of 89.7%67.

glioma60.

*f. Reprogramming energy metabolism* 

in different types of cancers (e.g., LOH on chromosome 14q32.31, or the amplification of chromosome 13q31.3). Together, these findings suggest that NPCs may be the originating cells in gliomas and that aberrations in critical regions might be necessary to maintain the stem cell nature of gliomas20.

A recent paper analyzed microRNA expression data from The Cancer Genome Atlas (TCGA) and identified five clinically and genetically distinct glioblastoma subclasses related to a different neural precursor cell types. Thus, like us they also suggested that glioblastomas can arise from neural precursor cells but emphasized that the cell of origin could arise from multiple stages of differentiation68.

### **6. microRNAs as biomarkers for the diagnosis and prognosis of gliomas**

As reviewed above, a large number of recent studies have discovered that miRNAs play important regulatory roles in a variety of cellular functions in gliomas. Other papers have demonstrated that miRNAs can be used for tumor classification and grading66,67 in addition to the diagnosis23, prognosis22,23 and prediction of therapeutic efficacy69, 69 of tumors. The discovery of miRNAs in the serum of cancer patients70 opened up the exciting possibility of using miRNAs as non-invasive biomarkers. Thus, detecting and quantifying microRNAs may soon be used in routine clinical practice for diagnostic and prognostic glioma testing.

The expression levels of miR-18222 and miR-19623 are significant in correlation with World Health Organization glioma grading (P < 0.001). Multivariate analysis showed that the expression of both these miRNAs is a predictor of overall survival in glioblastoma patients 22,23. Analysis of miRNA expression data in glioblastoma patients (n = 222) derived from the TCGA dataset identified an expression signature of ten miRNAs that can predict glioblastoma (GBM) patient survival71. In astrocytomas, the downregulation of miR-137 has been shown to be associated with advanced clinical stages of the disease; and the low expression levels of miR-181b and miR-106a, or high expression of miR-21, are significantly associated with poor patient survival24. Several papers aimed to identify the miRNAs specifically involved in the acquisition of temozolomide (TMZ) resistance in glioblastoma. In one article, the authors established resistant variant U251R cells from a TMZ-sensitive glioblastoma cell line (U251MG) and performed miRNA microarray on both the resistant and sensitive cell lines. The results showed that miR-195, miR-455-3p and miR-10a\* were the three most upregulated miRNAs in the resistant cells. When miR-195 was reduced, the resistant cells displayed a moderate cell killing effect, and the combination with TMZ strongly enhanced this effect25. Another article examined the correlation between the expression levels of selected microRNAs in 22 primary glioblastomas with response to concomitant therapy (e.g., chemoradiotherapy with TMZ). They found that miR-181b and miR-181c were significantly downregulated in patients who responded to concomitant therapy compared to patients with progredient disease26.

Over many decades, it has been shown that cell-free DNA and RNA is present in the circulation and may represent potential biomarkers. We have demonstrated that tumorspecific DNA can be detected in the serum of glioma patients and is a potentially promising tool for brain tumor diagnosis72. Skog et al. was the first to demonstrate that

The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment 83

delivery systems is necessary before miRNAs can be used as therapeutic agents for the

• A number of miRNAs are upregulated in gliomas and appear to act as oncogenes while other miRNAs, are downregulated indicating a tumor suppressive nature. These onco-miRNAs and tumor suppressor miRNAs modulate key processes that promote gliomagenesis and tumor progression, such as sustaining proliferative signaling, evading growth suppressors, resisting cell death, inducing angiogenesis,

• Not only individual, but also miRNA clusters are deregulated in gliomas. Some, such the huge cluster of 53 miRNAs on chromosome 14q32.31 are downregulated in gliomas, and may act as a tumor suppressive miRNA clusters and others such as

activating invasion and metastasis and reprogramming energy metabolism

miR17-92 are upregulated and reportedly have a pro-oncogenic role in cancer. • Gliomas display miRNA expression profile that is similar to neural precursor cells. This result is compatible with the phenotypically resemble of part of the neoplastic cell populations within glioblastomas to undifferentiated or immature glial cells. • Detecting and quantifying microRNAs in tissue and serum will soon be routinely used for tumor classification and grading as well as diagnostic and prognostic testing

for gliomas and may assist with the design of personalized treatments.

[1] Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene

• Manipulating the expression of miRNAs that are involved in glioma biology might

[2] Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and

[3] Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on

[4] Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread

[5] Sen GL, Blau HM. Argonaute 2/RISC resides in sites of mammalian mRNA decay

[6] Yu Z, Jian Z, Shen SH, Purisima E, Wang E. Global analysis of microRNA target gene

known as cytoplasmic bodies. *Nat Cell Biol.* Jun 2005;7(6):633-636.

changes in protein synthesis induced by microRNAs. *Nature.* Sep 4

expression reveals that miRNA targets are lower expressed in mature mouse and Drosophila tissues than in the embryos. *Nucleic Acids Res.* 2007;35(1):152-164. [7] Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional

regulation by microRNAs: are the answers in sight? *Nat Rev Genet.* Feb

silencing. *Cell.* Jan 11 2008;132(1):9-14.

provide opportunities for brain tumor treatments.

timing. *Cell.* Jun 13 2003;113(6):673-676.

2008;455(7209):58-63.

2008;9(2):102-114.

protein output. *Nature.* Sep 4 2008;455(7209):64-71.

treatment of malignant gliomas.

**At a glance:** 

**8. References**

brain microvascular endothelial cells take up exosomes, which contain mRNA, miRNA, and angiogenic proteins released by glioblastoma cells. Moreover, they showed that miR-21 is more elevated in serum microvesicles from glioblastoma patients than in healthy controls73.

Based on their potential as prognostic and diagnostic biomarkers, circulating miRNAs are promising non-invasive tumor markers. Tumor-specific circulating miRNAs may improve cancer diagnosis and prognosis because, as described above, several promising miRNAs have already been recognized as potential biomarkers for gliomas.

### **7. The therapeutic potential of microRNAs in gliomas**

With the increased understanding of the miRNA target genes, the cellular behaviors influenced by them and the ability of one microRNA, such as let-7 or miR-21, to target more than one gene or pathway provide exciting opportunities to use miRNAs or their inhibitors as potential candidates for the treatment of brain tumors.

There have been few pre-clinical and phase I/II studies that showed some success in using synthetic miRNA mimics or anti-miRNA oligonucleotides as therapeutic agents. Two of these studies demonstrated that delivery of the locked-nucleic-acid (LNA)-anti-miR in African green monkeys silences miR-122, decreases the total plasma cholesterol74 and suppresses HCV viremia75 with no evidence of hepatotoxicity. Another study showed that the silencing of miR-155 in a mouse inflammation model by LNA-anti-miR administration results in derepression of the C/EBP Beta isoforms and downregulation of granulocytecolony stimulating factor expression in mouse splenocytes76. In gliomas, the silencing of miR-21 by LNA-anti-miR followed by TRAIL treatment increased caspase activity *in vitro* and reduced tumor growth *in vivo*10. These results support the potential of LNA-anti-miR as therapeutics for inhibition of disease-associated miRNAs.

An alternative to chemically modified antisense oligonucleotides is the "miR sponge". These competitive miR inhibitors contain multiple binding sites to an miR of interest, preventing it from binding to its natural target. In this way, a single sponge can block all miR family members containing the same seed sequences. The sponge strategy has been used to inhibit miR-31 *in vivo* in a noninvasive breast cancer cell line. miR sponges that carried miR-31 recognition motifs were introduced into a retroviral vector and reduced miR-31 function significantly77.

Some preclinical studies have shown promising results using self-complementary adenoassociated viral (scAAV) vectors. For example, a scAAV vector containing miR-26a was administered with a single tail-vein injection into mice with established liver tumors. High miR-26a levels were found in their livers and no toxic effects were observed. While six out of eight mice treated with the control virus developed tumors, eight out of ten miR-26a-treated mice developed only small tumors or had a complete absence of tumors78.

Although most of these therapeutic approaches appear promising for systemic tumors, they would be considerably challenging in brain tumors due to several obstacles and barriers *in vivo,* such as the blood–brain barrier27, which might prevent the miRNAs or their antagonists from entering the brain. Thus, the development of more efficient and specific delivery systems is necessary before miRNAs can be used as therapeutic agents for the treatment of malignant gliomas.

#### **At a glance:**

82 Novel Therapeutic Concepts in Targeting Glioma

brain microvascular endothelial cells take up exosomes, which contain mRNA, miRNA, and angiogenic proteins released by glioblastoma cells. Moreover, they showed that miR-21 is more elevated in serum microvesicles from glioblastoma patients than in healthy

Based on their potential as prognostic and diagnostic biomarkers, circulating miRNAs are promising non-invasive tumor markers. Tumor-specific circulating miRNAs may improve cancer diagnosis and prognosis because, as described above, several promising miRNAs

With the increased understanding of the miRNA target genes, the cellular behaviors influenced by them and the ability of one microRNA, such as let-7 or miR-21, to target more than one gene or pathway provide exciting opportunities to use miRNAs or their inhibitors

There have been few pre-clinical and phase I/II studies that showed some success in using synthetic miRNA mimics or anti-miRNA oligonucleotides as therapeutic agents. Two of these studies demonstrated that delivery of the locked-nucleic-acid (LNA)-anti-miR in African green monkeys silences miR-122, decreases the total plasma cholesterol74 and suppresses HCV viremia75 with no evidence of hepatotoxicity. Another study showed that the silencing of miR-155 in a mouse inflammation model by LNA-anti-miR administration results in derepression of the C/EBP Beta isoforms and downregulation of granulocytecolony stimulating factor expression in mouse splenocytes76. In gliomas, the silencing of miR-21 by LNA-anti-miR followed by TRAIL treatment increased caspase activity *in vitro* and reduced tumor growth *in vivo*10. These results support the potential of LNA-anti-miR as

An alternative to chemically modified antisense oligonucleotides is the "miR sponge". These competitive miR inhibitors contain multiple binding sites to an miR of interest, preventing it from binding to its natural target. In this way, a single sponge can block all miR family members containing the same seed sequences. The sponge strategy has been used to inhibit miR-31 *in vivo* in a noninvasive breast cancer cell line. miR sponges that carried miR-31 recognition motifs were introduced into a retroviral vector and reduced miR-31 function

Some preclinical studies have shown promising results using self-complementary adenoassociated viral (scAAV) vectors. For example, a scAAV vector containing miR-26a was administered with a single tail-vein injection into mice with established liver tumors. High miR-26a levels were found in their livers and no toxic effects were observed. While six out of eight mice treated with the control virus developed tumors, eight out of ten miR-26a-treated

Although most of these therapeutic approaches appear promising for systemic tumors, they would be considerably challenging in brain tumors due to several obstacles and barriers *in vivo,* such as the blood–brain barrier27, which might prevent the miRNAs or their antagonists from entering the brain. Thus, the development of more efficient and specific

mice developed only small tumors or had a complete absence of tumors78.

have already been recognized as potential biomarkers for gliomas.

**7. The therapeutic potential of microRNAs in gliomas** 

as potential candidates for the treatment of brain tumors.

therapeutics for inhibition of disease-associated miRNAs.

controls73.

significantly77.


#### **8. References**


The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment 85

[25] Ujifuku K, Mitsutake N, Takakura S, et al. miR-195, miR-455-3p and miR-10a( \*) are

[26] Slaby O, Lakomy R, Fadrus P, et al. MicroRNA-181 family predicts response to

[27] Purow B. The elephant in the room: do microRNA-based therapies have a realistic

[28] Kiriakidou M, Tan GS, Lamprinaki S, De Planell-Saguer M, Nelson PT, Mourelatos Z.

[29] Chendrimada TP, Finn KJ, Ji X, et al. MicroRNA silencing through RISC recruitment of

[30] Beilharz TH, Humphreys DT, Clancy JL, et al. microRNA-mediated messenger RNA

[31] Bagga S, Bracht J, Hunter S, et al. Regulation by let-7 and lin-4 miRNAs results in target

[32] Behm-Ansmant I, Rehwinkel J, Izaurralde E. MicroRNAs silence gene expression by

[33] Wu L, Belasco JG. Micro-RNA regulation of the mammalian lin-28 gene during

[34] Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M, Izaurralde E.

[35] Yao B, Li S, Lian SL, Fritzler MJ, Chan EK. Mapping of Ago2-GW182 functional

[36] Eulalio A, Rehwinkel J, Stricker M, et al. Target-specific requirements for enhancers of

[37] Pauley KM, Eystathioy T, Jakymiw A, Hamel JC, Fritzler MJ, Chan EK. Formation of

[38] Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth

[39] Wulczyn FG, Smirnova L, Rybak A, et al. Post-transcriptional regulation of the let-7 microRNA during neural cell specification. *FASEB J.* Feb 2007;21(2):415-426. [40] Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. *RNA.* Aug 2008;14(8):1539-1549.

*Cancer Lett.* Oct 28 2010;296(2):241-248.

*Neoplasma.* 2010;57(3):264-269.

*Cell.* Jun 15 2007;129(6):1141-1151.

*Symp Quant Biol.* 2006;71:523-530.

*Res.* May 15 2008;68(10):3566-3572.

*One.* 2009;4(8):e6783.

2005;25(21):9198-9208.

32.

2570.

910.

eIF6. *Nature.* Jun 14 2007;447(7146):823-828.

mRNA degradation. *Cell.* Aug 26 2005;122(4):553-563.

interactions. *Methods Mol Biol.* 2011;725:45-62.

2010.

implicated in acquired temozolomide resistance in glioblastoma multiforme cells.

concomitant chemoradiotherapy with temozolomide in glioblastoma patients.

chance of succeeding for brain tumors such as glioblastoma? *J Neurooncol.* Nov 17

An mRNA m7G cap binding-like motif within human Ago2 represses translation.

deadenylation contributes to translational repression in mammalian cells. *PLoS* 

repressing protein expression and/or by promoting mRNA decay. *Cold Spring Harb* 

neuronal differentiation of embryonal carcinoma cells. *Mol Cell Biol.* Nov

Deadenylation is a widespread effect of miRNA regulation. *RNA.* Jan 2009;15(1):21-

decapping in miRNA-mediated gene silencing. *Genes Dev.* Oct 15 2007;21(20):2558-

GW bodies is a consequence of microRNA genesis. *EMBO Rep.* Sep 2006;7(9):904-

factor receptor and the Akt pathway and is down-regulated in glioblastoma. *Cancer* 


[8] Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of

[9] Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E. MicroRNA-10b is

[10] Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-

[11] Gabriely G, Wurdinger T, Kesari S, et al. MicroRNA 21 promotes glioma invasion by

[12] Li Y, Guessous F, Zhang Y, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. *Cancer Res.* Oct 1 2009;69(19):7569-7576. [13] Guessous F, Zhang Y, Kofman A, et al. microRNA-34a is tumor suppressive in brain

[14] Gillies JK, Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. *Cell* 

[15] Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome

[16] Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stem cell

[17] Kefas B, Comeau L, Floyd DH, et al. The neuronal microRNA miR-326 acts in a

[18] Lee ST, Chu K, Oh HJ, et al. Let-7 microRNA inhibits the proliferation of human

[19] Huse JT, Brennan C, Hambardzumyan D, et al. The PTEN-regulating microRNA miR-

[20] Lavon I, Zrihan D, Granit A, et al. Gliomas display a microRNA expression profile reminiscent of neural precursor cells. *Neuro Oncol.* May 2010;12(5):422-433. [21] Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer

[22] Jiang L, Mao P, Song L, et al. miR-182 as a prognostic marker for glioma progression

[23] Guan Y, Mizoguchi M, Yoshimoto K, et al. MiRNA-196 is upregulated in glioblastoma

[24] Zhi F, Chen X, Wang S, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. *Eur J Cancer.* Jun 2010;46(9):1640-1649.

but not in anaplastic astrocytoma and has prognostic significance. *Clin Cancer Res.* 

network. *Int J Biochem Cell Biol.* Aug 2010;42(8):1348-1354.

and patient survival. *Am J Pathol.* Jul 2010;177(1):29-38.

survivorship. *Proc Natl Acad Sci U S A.* Feb 2 2010;107(5):2183-2188.

analysis reveals an oncomir/oncogene cluster regulating glioblastoma

renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal.

feedback loop with notch and has therapeutic potential against brain tumors. *J* 

26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. *Genes* 

uPAR and RhoC. *Int J Cancer.* Sep 15 2009;125(6):1407-1413.

tumors and glioma stem cells. *Cell Cycle.* Mar 18 2010;9(6).

*BMC Med.* 2008;6:14.

2007;67(19):8994-9000.

*Cycle.* Aug 15 2007;6(16):2005-2009.

*Cancer Res.* Nov 15 2008;68(22):9125-9130.

*Neurosci.* Dec 2 2009;29(48):15161-15168.

*Dev.* Jun 1 2009;23(11):1327-1337.

Aug 15 2010;16(16):4289-4297.

glioblastoma cells. *J Neurooncol.* Jul 7 2010.

5380.

glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

overexpressed in malignant glioma and associated with tumor invasive factors,

21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. *Cancer Res.* Oct 1

targeting matrix metalloproteinase regulators. *Mol Cell Biol.* Sep 2008;28(17):5369-


The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment 87

[59] Wurdinger T, Tannous BA, Saydam O, et al. miR-296 regulates growth factor receptor

[60] Xia H, Qi Y, Ng SS, et al. microRNA-146b inhibits glioma cell migration and invasion by

[61] Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. *Semin Cancer Biol.* Aug 2005;15(4):300-308. [62] Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B. Pyruvate kinase M2 is a

[63] Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. *Biochem Biophys Res Commun.* Sep 9 2005;334(4):1351-1358. [64] Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human

[65] Nelson PT, Baldwin DA, Kloosterman WP, Kauppinen S, Plasterk RH, Mourelatos Z.

[66] Malzkorn B, Wolter M, Liesenberg F, et al. Identification and functional characterization

[67] Rao SA, Santosh V, Somasundaram K. Genome-wide expression profiling identifies

[68] Kim TM, Huang W, Park R, Park PJ, Johnson MD. A Developmental Taxonomy of

[70] Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated

[71] Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature

[72] Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-

[73] Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and

[74] Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human

[75] Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-

predicts survival in glioblastoma. *PLoS One.* 2011;6(3):e17438.

targeting MMPs. *Brain Res.* May 7 2009;1269:158-165.

glioma cells. *Neuro Oncol.* Nov 2010;12(11):1102-1112.

human brain. *RNA.* Feb 2006;12(2):187-191.

2010;20(3):539-550.

2011;71(9):3387-3399.

May 2008;141(5):672-675.

Feb 2010;12(2):173-180.

2010;327(5962):198-201.

*Biol.* Dec 2008;10(12):1470-1476.

primates. *Nature.* Apr 17 2008;452(7189):896-899.

[69] !!! INVALID CITATION !!!

1417.

glioblastoma cells. *Cancer Res.* Jul 15 2005;65(14):6029-6033.

393.

overexpression in angiogenic endothelial cells. *Cancer Cell.* Nov 4 2008;14(5):382-

target of the tumor-suppressive microRNA-326 and regulates the survival of

RAKE and LNA-ISH reveal microRNA expression and localization in archival

of microRNAs involved in the malignant progression of gliomas. *Brain Pathol.* May

deregulated miRNAs in malignant astrocytoma. *Mod Pathol.* Oct 2010;23(10):1404-

Glioblastoma Defined and Maintained by MicroRNAs. *Cancer Res.* May 1

microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br J Haematol.* 

specific genetic and epigenetic markers in gliomas of various grades. *Neuro Oncol.* 

proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell* 

122 in primates with chronic hepatitis C virus infection. *Science.* Jan 8


[41] Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7

[42] Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently

[43] Makunin IV, Pheasant M, Simons C, Mattick JS. Orthologous microRNA genes are

[44] Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human

[45] Ando T, Yoshida T, Enomoto S, et al. DNA methylation of microRNA genes in gastric

[46] Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an

[48] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* Mar 4

[49] Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of

[50] Talotta F, Cimmino A, Matarazzo MR, et al. An autoregulatory loop mediated by miR-

[51] Gaur AB, Holbeck SL, Colburn NH, Israel MA. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. *Neuro Oncol.* Jun 2011;13(6):580-590. [52] Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. *Nat Rev Mol Cell Biol.* Jan

[53] Medina R, Zaidi SK, Liu CG, et al. MicroRNAs 221 and 222 bypass quiescence and

[54] Zhang J, Han L, Ge Y, et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. *Int J Oncol.* Apr 2011;36(4):913-920. [55] Gabriely G, Yi M, Narayan RS, et al. Human Glioma Growth Is Controlled by

[56] Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid

[57] Zhang CZ, Zhang JX, Zhang AL, et al. MiR-221 and miR-222 target PUMA to induce cell

[58] Wang S, Olson EN. AngiomiRs--key regulators of angiogenesis. *Curr Opin Genet Dev.* 

compromise cell survival. *Cancer Res.* Apr 15 2008;68(8):2773-2780.

apoptosis of colorectal cancer cells. *Mol Cell.* Mar 2001;7(3):673-682.

MicroRNA-10b. *Cancer Res.* May 15 2011;71(10):3563-3572.

survival in glioblastoma. *Mol Cancer.* 2010;9:229.

epigenetic field defect. *Int J Cancer.* May 15 2009;124(10):2367-2374.

[47] Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* Jan 7 2000;100(1):57-70.

Aug 2008;10(8):987-993.

2007;2(11):e1133.

15 2007;67(4):1419-1423.

2011;144(5):646-674.

2009;28(1):73-84.

2002;3(1):11-20.

Jun 2009;19(3):205-211.

*U S A.* Mar 2 2004;101(9):2999-3004.

cancer cells. *Cell Cycle.* Oct 2006;5(19):2220-2222.

*Biol Chem.* Feb 27 2009;284(9):5731-5741.

controls pre-let-7 maturation during neural stem-cell commitment. *Nat Cell Biol.* 

located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci* 

located in cancer-associated genomic regions in human and mouse. *PLoS One.* 

mucosae of gastric cancer patients: its possible involvement in the formation of

epigenetically regulated microRNA gene with oncogenic function. *Cancer Res.* Feb

epidermal growth factor receptor signaling in human cancer cells by microRNA-7. *J* 

21 and PDCD4 controls the AP-1 activity in RAS transformation. *Oncogene.* Jan 8


**Part 4** 

**Inhibition of Invasion in Treatment of Glioma** 

